WASHINGTON, April 6, 2016 /PRNewswire-USNewswire/ --Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on yesterday's decision by the Food and Drug Administration (FDA) to approve Inflectra, the second biosimilar approved in the United States. Inflectra will compete with Remicade to treat Crohn's disease and rheumatoid arthritis, among other conditions.
"The FDA is taking important steps toward approving more biosimilars in the United States. Increasing competition through the approval of brand and generic drug competitors is the key to lowering prescription drug costs for consumers, employers, government programs, and others.
To further advance the use of biosimilars, the FDA should finalize an interchangeability policy that will allow for greater patient access to these important drugs."
PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pcma-statement-on-the-fdas-decision-to-approve-the-second-us-biosimilar-300247282.html
SOURCE Pharmaceutical Care Management Association